← Back to Home

Beren Therapeutics

Private
#Ultra-Rare Genetic Disorders#Inborn Errors of Metabolism#Neuromuscular Rare Disease#Pediatric Genetic Disease#Antisense Oligonucleotide Therapy

Beren Therapeutics is a private late-stage rare-disease biotechnology company developing precision therapies for ultra-rare genetic disorders, with a lead program approaching an FDA filing. The company leverages patient-specific genetic insights to develop targeted small-molecule and antisense therapies.

Company Info

Sector:Biotechnology / Rare Disease
Headquarters:Boston, Massachusetts, USA
Founded:2021
Website:www.berentx.com/
Funding Round:Series C June 2026 ($300M) on path to FDA filing
Total Funding:$500M+ (cumulative)

Funding & Investor Relations

Notable Investors

  • Atlas Venture
  • OrbiMed
  • RA Capital Management
  • Bain Capital Life Sciences
  • Perceptive Advisors
  • Surveyor Capital

IPO Outlook / Plans

Pre-IPO; considering public offering following FDA decision in 2027.

Upcoming Milestones & Key Dates

Late 2026
Regulatory

FDA NDA submission for BER-101 lead rare disease program

H1 2027
Regulatory

Anticipated FDA decision (PDUFA) on BER-101

Clinical Development Pipeline

BER-101

Target: Disease-modifying small molecule
Ultra-rare inborn error of metabolism (lead program, undisclosed target)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BER-201

Target: Antisense oligonucleotide targeting toxic transcript
Rare neuromuscular disorder
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BER-301

Target: Liver-targeted ASO
Pediatric rare liver disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Dr. Priyanka Bakhtiani

Co-Founder and Chief Executive Officer

Dr. Aleksandar Rajkovic

Chief Medical Officer

Dr. Marla Weetall

Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →